Subclinical Ventricular Dysfunction Detected by Speckle-Tracking Two Years after Use of Anthracycline
| Autor: | Salvador Rassi, Aguinaldo F. Freitas Jr, Raquel Oliveira Santos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Dis função Vent ricular Esquerda/induzido quimicamente
medicine.medical_specialty lcsh:Diseases of the circulatory (Cardiovascular) system Side effect Anthracycline medicine.drug_class chocardiography Diastole Anthracyclines/adverse effects Ventricular Dysfunction Left Internal medicine medicine Humans Antihypertensive drug Antraciclinas/efeitos adversos Letter to the Editor Subclinical infection Heart Failure Cardiotoxicity Antibiotics Antineoplastic business.industry Incidence (epidemiology) Echocardiography Doppler lcsh:RC666-701 Doxorubicin Cardiology Female Insuf iciência Cardíaca Cardiology and Cardiovascular Medicine Complication business Ventricular Dysfunction Left/chemically induced Ecocardiografia |
| Zdroj: | Arquivos Brasileiros de Cardiologia Arquivos Brasileiros de Cardiologia, Vol 105, Iss 2, Pp 206-207 (2015) |
| ISSN: | 1678-4170 0066-782X |
| Popis: | Dear Editor We would like to congratulate the authors for the publication of their article "Subclinical Ventricular Dysfunction Detected by Speckle-Tracking Two Years after Use of Anthracycline", considering the great practical applicability of the theme. Cardiotoxicity secondary to chemotherapy drugs is a reality that imposes, on cardiologists and oncologists, the challenge of prevention and/or early detection of this complication, which has high morbidity and mortality1. In this regard, we read with interest the abovementioned article, which highlights the usefulness of speckle-tracking to attain an early diagnosis of subclinical ventricular dysfunction, although this finding does not directly imply in implementing treatment due to the lack of current scientific evidence, which makes studies in this area even more important. However, we would like to point out some aspects to add to the scientific information brought on by this article. In the Results section, the authors demonstrate that almost 80% of patients had also received cyclophosphamide as a chemotherapy drug, an alkylating agent that may be associated with ventricular dysfunction rates of up to 25% of the cases2,3, which cannot be minimized in the Discussion and Conclusion sections of this study. This same rationale can be applied to the more than 50% of patients receiving radiotherapy in the mediastinal region, regardless of the treated hemithorax, since the incidence of coronary heart disease in these patients is a side effect of significant incidence4. We also observed a high rate of hypertension in both groups of patients and controls and that the systolic and diastolic BP levels were higher in the latter than in the first group. We would like to know if there was any difference between the groups regarding the class of antihypertensive drug used, as data in the literature suggest some protective effect of ACE inhibitors and beta-blockers on the incidence of ventricular dysfunction and major clinical outcomes5. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|